Results 41 to 50 of about 77,574 (220)

Lyme Disease Biobank: 10 years of 3 month follow-up visits from 2014 to 2023

open access: yesFrontiers in Medicine
IntroductionLyme Disease Biobank (LDB) enrolls participants with signs and symptoms of early Lyme disease (LD) from endemic areas and makes samples available to researchers developing more accurate diagnostics. From 2014 to 23, 466 cases and 367 controls
Elizabeth J. Horn   +7 more
doaj   +1 more source

Lyme Disease in Fairfield County, Connecticut: The Need to Know [PDF]

open access: yes, 2019
There has been a steady rise in number of cases reported of Lyme disease in the past 25 years. In fact, it is the 7th most common reportable infectious disease in US with an estimated over 300,000 people diagnosed and treated each year. The total medical
Chen, Jack
core   +1 more source

Variations in Ixodes ricinus Density and Borrelia Infections Associated with Cattle Introduced into a Woodland in The Netherlands [PDF]

open access: yes, 2008
The effect of introduced large herbivores on the abundance of Ixodes ricinus ticks and their Borrelia infections was studied in a natural woodland in The Netherlands. Oak and pine plots, either ungrazed or grazed by cattle, were selected.
Gassner, F.   +5 more
core   +2 more sources

Clinical Practice Guideline for Evaluation and Management of Peripheral Nervous System Manifestations in Sjögren's Disease

open access: yesArthritis Care &Research, EarlyView.
Objective Sjögren's disease is an autoimmune disorder that can impact multiple organ systems, including the peripheral nervous system (PNS). PNS manifestations, which can exist concurrently, include mononeuropathies, polyneuropathies, and autonomic nervous system neuropathies.
Anahita Deboo   +88 more
wiley   +1 more source

Epidemiology and risk factors of Lyme disease in Taiwan from 2007 to 2020

open access: yesJournal of Medical Sciences, 2023
Background: Lyme disease or Lyme borreliosis is the most commonly transmitted tick-borne infection in the United States and among the most frequently diagnosed tick-borne infections worldwide. Lyme disease is caused by Borrelia burgdorferi.
Chi-Jeng Hsieh   +5 more
doaj   +1 more source

Education on Tickborne Diseases and Prevention Strategies [PDF]

open access: yes, 2017
Research suggests that around 300,000 people are diagnosed with Lyme disease each year and that around one billion dollars is spent on healthcare for Lyme disease alone.
Bernard, Christopher
core   +1 more source

The Heterogeneity, Distribution, and Environmental Associations of Borrelia burgdorferi Sensu Lato, the Agent of Lyme Borreliosis, in Scotland [PDF]

open access: yes, 2014
Genospecies controls were obtained from the laboratory of Dr. Muriel Cornet at the Institut Pasteur, Paris. We thank Bob Furness for collecting ticks from passerine birds, Steph Vollmer for processing the samples from one site, E. Packer, A.
Bowman, Alan S   +3 more
core   +4 more sources

Discovery of an Adaptive Neuroimmune Response Driving Itch and Fast Tick Removal with Implications for Preventing Pathogen Transmission

open access: yesAdvanced Science, EarlyView.
Itch‐induced tick removal (IITR): An acquired neuroimmune mechanism, itch‐induced tick removal, develops after repeated tick exposure, mobilizing T cells and macrophages at the tick bite site to trigger a rapid scratching response that facilitates timely tick removal within a critical window that precedes the transmission of many tick‐borne pathogens ...
Johannes S. P. Doehl   +27 more
wiley   +1 more source

Parallelisms and Contrasts in the Diverse Ecologies of the Anaplasma phagocytophilum and Borrelia burgdorferi Complexes of Bacteria in the Far Western United States. [PDF]

open access: yes, 2016
Anaplasma phagocytophilum and Borrelia burgdorferi are two tick-borne bacteria that cause disease in people and animals. For each of these bacteria, there is a complex of closely related genospecies and/or strains that are genetically distinct and have ...
Foley, Janet, Stephenson, Nicole
core   +2 more sources

Efficacy and Safety of Guselkumab in Participants With Active Psoriatic Arthritis After Inadequate Response to One Prior Tumor Necrosis Factor Inhibitor: Week‐24 Results of a Phase 3, Randomized, Placebo‐Controlled Study

open access: yesArthritis &Rheumatology, EarlyView.
Objective To evaluate the efficacy and safety of guselkumab, an interleukin‐23p19 subunit inhibitor, in participants with active psoriatic arthritis (PsA) and inadequate response (inadequate efficacy and/or intolerance) to one prior tumor necrosis factor (TNF) inhibitor.
Alexis Ogdie   +12 more
wiley   +1 more source

Home - About - Disclaimer - Privacy